Reducing the risk of perinatal HIV-1 transmission with zidovudine: Results and implications of AIDS Clinical Trials Group protocol 076

Acta Paediatrica, International Journal of Paediatrics, Supplement

Volumn 86, Issue 421, 1997, Pages 89-96

  Mofenson, L M ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; PATIENT COUNSELING; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; VERTICAL TRANSMISSION; VIRUS TRANSMISSION; ADULT; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COUNSELING; DISEASE TRANSMISSION; FEMALE; GESTATIONAL AGE; HUMAN; MANDATORY TESTING; METHODOLOGY; NEWBORN; PRACTICE GUIDELINE; PREGNANCY; PREGNANCY COMPLICATION; RANDOMIZED CONTROLLED TRIAL; SERODIAGNOSIS;

ADULT; AIDS SERODIAGNOSIS; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COUNSELING; DISEASE TRANSMISSION, VERTICAL; FEMALE; GESTATIONAL AGE; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; MANDATORY TESTING; PRACTICE GUIDELINES; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; ZIDOVUDINE;

EID: 0030874295     PISSN: 08035326     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Davis SF, Byers RH, Lindegren ML, Caldwell MB, Karon JM, Gwinn M. Prevalence and incidence of vertically acquired HIV infection in the United States. J Am Med Assoc 1995; 247: 952-5
2. United Nations Development Programme. Young women: silence, susceptibility and the HIV epidemic. Pediatr AIDS HIV Infect Fetus Adolesc 1994; 5: 1-9
3. Nicoll A, Newell M-L, Van Praag E, Van der Perre P, Peckham C. Infant feeding policy and practice in the presence of HIV-1 infection. AIDS 1995; 9: 107-19
4. Chu SY, Buehler JW, Oxtoby MJ, Kilbourne BW. Impact of human immunodeficiency virus epidemic on mortality in children, United States. Pediatrics 1991; 87: 806-11
5. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994; 331: 1173-80
6. O'Sullivan MJ, Boyer PJJ, Scott GB, et al. The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus: phase I Acquired Immunodeficiency Syndrome Clinical Trials Group study (protocol 082). Am J Obstet Gynecol 1993; 168: 1510-6
7. Sperling RS, Shapiro DE, Coombs R, et al. Maternal viral load, zidovudine treatment and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med 1996; 335: 1621-9
8. Centers for Disease Control. Recommendations of the U.S. Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. Morbid Mortal Weekly Rep 1994; 43(RR-11): 1-20
9. Centers for Disease Control. U.S. Public Health Service recommendations for human immunodeficiency virus counseling and voluntary testing for pregnant women. Morbid Mortal Weekly Rep 1995; 44(RR-7): 1-15
10. Ayers KM. Preclinical toxicology of zidovudine: an overview. Am J Med 1988; 85 Suppl 2A: 186-8
11. Lewis W, Simpson JF, Meyer RR. Cardiac mitochondrial DNA polymerase-gamma is inhibited competitively and non-competitively by phosphorylated zidovudine. Circ Res 1994; 74: 344-8
12. Domanski MJ, Sloas MM, Follmann DA, et al. Effect of zidovudine and didanosine treatment on heart function in children infected with human immunodeficiency virus. J Pediatr 1995; 127: 137-46
13. Lipshultz SE, Orav EJ, Sanders SP, Hale AR, McIntosh K, Colan SD. Cardiac structure and function in children with human immunodeficiency virus infection treated with zidovudine. N Engl J Med 1992; 18: 1260-5
14. Dalakas MC, Illa I, Pezeshkpour GH, Laukaitis JP, Cohen B, Griffen JL. Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 1990; 16: 1098-105
15. Centers for Disease Control. Birth outcomes following zidovudine therapy in pregnant women. Morbid Mortal Weekly Rep 1994; 43: 415-6
16. Sperling RS, Stratton P, O'Sullivan MJ, et al. A survey of zidovudine use in pregnant women with human immunodeficiency virus infection. N Engl J Med 1992; 326: 857-61
17. Ferrazin A, den Maria A, Gotta C, et al. Zidovudine therapy of HIV-1 infection during pregnancy: assessment of the effect on the newborns. J Acq Immune Defic Syndr 1993; 6: 376-9
18. Mofenson LM. Epidemiology and determinants of vertical HIV transmission. Sem Pediatr Infect Dis 1994; 5: 252-65
19. Sperling RS, Stratton P, and the members of the Obstetric-Gynecologic Working Group of the AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. Treatment options for human immunodeficiency virus-infected pregnant women. Obstet Gynecol 1992; 79: 443-8
20. Boyer PJ, Dillon M, Navaie M, et al. Factors predictive of maternal-fetal transmission of HIV-1: preliminary analysis of zidovudine given during pregnancy and/or delivery. J Am Med Assoc 1994; 271: 1925-30
21. Matheson PB, Abrams EJ, Thomas PJ, et al. Efficacy of antenatal zidovudine in reducing perinatal transmission of human immunodeficiency virus type 1. J Infect Dis 1995; 172: 353-8
22. Erice A, Balfour JH. Resistance of human immunodeficiency virus type 1 to antiretroviral agents: a review. Clin Infect Dis 1994; 18: 149-56
23. Richman DD. Clinical significance of drug resistance in human immunodeficiency virus. Clin Infect Dis 1995; 21 Suppl 2: S166-9
24. Wainberg MA, Beaulieu R, Tsoukas C, Thomas R. Detection of zidovudine-resistant variants of HIV-1 in genital fluids. AIDS 1993; 7: 433-4
25. Barzilai A, Sperling RS, Hyatt AC, Wedgwood JF, Reidenberg BE, Hodes D. Mother to child transmission of human immunodeficiency virus type 1 infection despite zidovudine therapy from 18 weeks gestation. Pediatr Infect Dis J 1990; 9: 931-3
26. Siegrist C-A, Yerly S, Kaiser L, Wyler C-A, Perrin L. Mother to child transmission of zidovudine-resistant HIV-1. Lancet 1994; 344: 1771-2
27. Tokars JI, Marcus R, Culver DH, et al. Surveillance of HIV infection and zidovudine use among health care workers after occupational exposrue to HIV-infected blood. Ann Intern Med 1993; 118: 913-9
28. Centers for Disease Control. Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood - France, United Kingdom, and United States, January 1988-August 1994. Morbid Mortal Weekly Rep 1995; 44: 929-33
29. Van Rompay KKA, Otsyula MG, Marthas ML, Miller CJ, McChesney MB, Pedersen NC. Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS. Antimicrob Agents Chemother 1995; 39: 125-31
30. Rausch DM, Heyes MP, Murray EA, Eiden LE. Zidovudine treatment prolongs survival and decreases viral load in the central nervous system of rhesus macaques infected perinatally with simian immunodeficiency virus. J Infect Dis 1995; 172: 59-69
31. Agency for Health Care Policy and Research. Evaluation and management of early HIV infection. Publication Number 94-0572. Washington, DC: US Public Health Service, 1994
32. Working Group on Antiretroviral Therapy. National Pediatric HIV Resource Center. Antiretroviral therapy and medical management of the human immunodeficiency virus-infected child. Pediatr Infect Dis J 1993; 12: 513-22
33. Provisional Committee on Pediatric AIDS. Perinatal human immunodeficiency virus testing. Pediatrics 1995; 95: 303-7
34. Centers for Disease Control. Update: AIDS among women - United States, 1994. 1995; 44: 81-4
35. Coplan J, Dye TD, Contello KA, Cunningham CK, Kirkwood K, Weiner LB. Failure to identify human immunodeficiency virus-seropositive newborns: epidemiology and enrollment patterns in a predominantly white, nonurban setting. Pediatrics 1995; 96: 1083-9
36. Barbacci M, Repke JT, Chaisson RE. Routine prenatal screening for HIV infection. Lancet 1991; 337: 709-11
37. Wasser SC, Gwinn M, Fleming P. Urban-nonurban distribution of HIV infection in childbearing women in the United States. J Acq Immune Defic Syndr 1993; 6: 1035-42
38. Simonds RJ, Lindegren ML, Thomas P, et al. Prophylaxis against Pneumocystis carinii pneumonia among children with perinatally acquired HIV infection in the United States. N Engl J Med 1995; 332: 786-90
39. Centers for Disease Control. 1995 revised guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with or perinatally exposed to human immunodeficiency virus. Morbid Mortal Weekly Rep 1995; 44(RR-4): 1-11
40. Minkoff H, Willoughby A. Pediatric HIV disease, zidovudine in pregnancy and unblinding heelstick surveys: reframing the debate on prenatal HIV testing. J Am Med Assoc 1995; 274: 1165-8
41. Lindsay MK, Feng TI, Peterson HB, Slade BA, Willis S, Klein L. Routine human immunodeficiency virus infection screening in unregistered and registered inner-city parturients. Obstet Gynecol 1991; 77: 599-603
42. Lindsay MK. A protocol for routine voluntary antepartum human immunodeficiency virus antibody screening. Obstet Gynecol 1993; 168: 476-9
43. Lewis R, O'Brien JM, Ray DT, Sibai BM. The impact of initiating a human immunodeficiency virus screening program in an urban obstetric population. Am J Obstet Gynecol 1995; 173: 1329-33
44. Rogers MF, Mofenson LM, Moseley RR. Reducing the risk of perinatal HIV transmission through zidovudine therapy: treatment recommendations and implications. J Am Med Womens Assoc 1995; 50: 78-93